Endothelin receptor antagonists ambrisentan

Bosentan is a nonselective receptor blocker. It is active orally, and blocks both the initial transient depressor (ETB) and the prolonged pressor ( ) responses to intravenous endothelin. Many orally active endothelin receptor antagonists with increased selectivity have been developed and are available for research use. Examples include the selective antagonists sitaxsentan and ambrisentan. 

Liver The availability of ambrisentan in patients with pulmonary artery hypertension who have previously discontinued other endothelin receptor antagonists because of liver function abnormalities provides an important option for patients who have had adverse reactions to bosentan or sitaxsentan [76 ]. Ambrisentan is a... 

The use of endothelin receptor antagonists for pulmonary hypertension has been examined in 14 high-risk adults with sickle cell disease [81 ]. Most were taking bosentan and three were taking ambrisentan. There were similar adverse effects as in previous studies, including rises in serum alanine aminotransferase n = 2), peripheral edema (4), rash (1), headache (3), and reduced hemoglobin (2), none of which required drug withdrawal. 

---